SMC IMPACT project
SMC Impact is a project that will assess the impact of SMC (seasonal malaria chemoprevention) and introduce into key countries an additional artemisinin combination therapy (ACT) to complement existing therapeutic treatment tools.
Target countries for the project
Nigeria, The Gambia, Niger, Mali, Guinea
- Contribute to covering the remaining gaps for the current eligible target.
- Contribute to the body of evidence about:
- Efficacy and cost effectiveness of increasing SMC to 5-10 years old children.
- Added impact of adding an additional month of SMC coverage during the transmission season.
- Develop an alternative SMC regimen based on the existing regimen, sulfadoxine pyrimethamine (SPAQ), for children aged 5-10 years old.
- Contribute to increasing knowledge about a new artemisinin-based combination therapy, Pyramax®, and introduction in malaria endemic countries as an alternative therapeutic solution.
Catholic Relief Services (CRS); London School of Health and Tropical Medicine (LSHTM) and Malaria Consortium (MC)
Korea International Cooperation Agency (KOICA) Global Disease Eradication Fund (GDEF)